Adnexus Therapeutics Announces Additional Phase I and Preclinical Data on CT-322 at 6th International Congress on Targeted Therapies in Cancer.WALTHAM, Mass. -- Adnexus Therapeutics, Inc. today announced that the company presented additional Phase I and preclinical data on Angiocept (CT-322), the company's novel anti-angiogenesis agent, at The 6th International Congress on Targeted Therapies in Cancer that was held in Washington, DC at the Renaissance Mayflower Hotel
Title: "Adnectins - A novel class of protein therapeutics" Speaker: Eric Furfine, Ph.D., SVP SVP S'il Vous Plaît (French: Please) SVP Senior Vice President SVP Schweizerische Volkspartei (Swiss People~s Party) SVP Society of Vertebrate Paleontology SVP Social Venture Partners SVP St Vincent de Paul of Research and Preclinical Development at Adnexus Saturday, August 25th at 1:30pm. Title: "Phase I data with Adnectins" Speaker: Christopher, Sweeney, M.D., Indiana University Indiana University, main campus at Bloomington; state supported; coeducational; chartered 1820 as a seminary, opened 1824. It became a college in 1828 and a university in 1838. The medical center (run jointly with Purdue Univ. Saturday, August 25th at 1:50pm. Angiocept (CT-322), Adnexus' first drug candidate, is in an ongoing Phase 1 trial in oncology in the United States. Angiocept is an Adnectin that was designed to be both a potent and highly specific antagonist of the vascular endothelial growth factor Vascular endothelial growth factor (VEGF) is an important signaling protein involved in both vasculogenesis (the de novo formation of the embryonic circulatory system) and angiogenesis (the growth of blood vessels from pre-existing vasculature). receptor 2 (VEGFR-2). VEGFR-2 activation is believed to be the primary driver of the growth of new blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. that support tumor growth. Angiocept has been demonstrated in preclinical studies preclinical studies, n.pl a term used to describe research done before a clinical study. May be laboratory or epidemiologic research. to block activation of VEGFR-2 by all of its known protein activators, VEGF-A, VEGF-C, and VEGF-D. Adnectins are a novel, proprietary class of targeted biologics that are derived from a well-characterized protein, fibronectin, that is prevalent throughout the human body. Adnexus is the exclusive developer of Adnectins. About Adnexus Therapeutics Adnexus Therapeutics is focused on generating vital medicines through the discovery, development, and commercialization of a new class of drugs, Adnectins. Adnexus' first product candidate, Angiocept (CT-322), is in Phase 1 clinical development in oncology in the United States. The company also has a pipeline of other Adnectin products in preclinical research across multiple therapeutic areas. Adnectins are designed and optimized using PROfusion, the company's patented protein design engine that enables rapid optimization of protein therapeutics. The company is funded by five leading venture capital firms Name Location Founding date Managing Partners/Directors Specialty Capital managed 5AM Ventures Menlo Park, CA; Waltham, MA 2002 John Diekman, PhD (managing partner), Scott Rocklage, PhD (managing partner), Andrew Schwab (managing partner) life sciences $200M [1] : Atlas Venture, Flagship Ventures, Polaris Venture Partners, Venrock, and HBM HBM Human Body Model HBM Human Brain Mapping HBM Hottinger Baldwin Messtechnik GmbH (German company) HBM High Bone Mass HBM Hybrid Bilayer Membrane HBM Humming Bird Medal HBM Her/His Britannic Majesty BioVentures. Adnectin[TM], Adnexus[TM] Therapeutics and PROfusion[TM] are trademarks of Adnexus[TM] Therapeutics, Inc. Adnexus(SM) Therapeutics is a service mark of Adnexus[TM] Therapeutics. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion